A Two Arm, Randomized, Prospective, Multicenter Study of Penpulimab Combined With Anlotinib Hydrochloride and Chemotherapy in the Perioperative Treatment of Locally Advanced Resectable Esophageal Cancer (EASOPCWAAC)

NCT06586242 Phase 2 RECRUITING

This study is a two arm, randomized, prospective, multicenter study on the perioperative treatment of locally advanced resectable esophageal cancer with penpulimab combined with anlotinib hydrochloride and chemotherapy.

Details

Lead sponsor	Xijing Hospital
Phase	Phase 2
Status	RECRUITING
Enrolment	194
Start date	2023-04-03
Completion	2036-04

Conditions

• Esophageal Cancer

Interventions

• Penpulimab;Anlotinib;albumin paclitaxel;oxaliplatin;lobaplatin

Primary outcomes

• the Pathological complete response (PCR) rate — 2years
  Pathological complete response (PCR) rate

Countries

China